Evidence map›Paper›PMID 31848942›Full record

ArticlePathology oncology research : POR2020

KIT Mutation Incidence and Pattern of Melanoma in Central Europe.

V Doma, T Barbai, M-A Beleaua, I Kovalszky, E Rásó, József Tímár

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathology oncology research : POR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Novel somatic Missense Mutations in Exon 11 of the KIT Gene are Detected in Melanoma.Asian Pacific journal of cancer prevention : APJCP · 2023
    Article
  8. Article
  9. Review
  10. Relevance of BRAF Subcellular Localization and Its Interaction withInternational journal of molecular sciences · 2021
    Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Cancer genomics & proteomics
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

V DomaDepartment of Dermatology, Semmelweis University, Budapest, Hungary.
T Barbai2nd Department of Pathology, Semmelweis University, Üllői 93., Budapest, H-1091, Hungary.
M-A BeleauaDepartment of Pathology, Pharmacy and Science, University of Medicine, Tirgu-Mures, Romania.
I Kovalszky1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
E Rásó2nd Department of Pathology, Semmelweis University, Üllői 93., Budapest, H-1091, Hungary.
József Tímár2nd Department of Pathology, Semmelweis University, Üllői 93., Budapest, H-1091, Hungary. jtimar@gmail.com.ORCID http://orcid.org/0000-0001-9183-0859
Semmelweis University · HUUniversitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș · RO

Funding

KTIA-NAPB 13-2-2014-0021NKFIH K-112371NVKP 16-1-2016-0004
6 · The paper itself

Abstract

Data on the KIT mutation rate in melanoma in the central European region is missing. Accordingly, in a cohort of 79 BRAF/NRAS double wild type cutaneous melanoma and 17 mucosal melanoma KIT mutation was assessed by Sanger sequencing of exons 9,11,13,17 and 18. In this cutaneous melanoma cohort KIT mutation frequency was found to be 34/79 (43.04%) with a significantly higher rate in acrolentiginous melanoma (ALM) as compared to UV-induced common variants (20/34, 58.8% versus 14/45, 31.1%, p = 0.014). In the double wild type mucosal melanoma cohort the KIT mutation frequency was found to be comparable (41.2%). The actual frequency of KIT mutation in the original 227 patient cutaneous melanoma cohort was 34/227, 14.9%. Exon 11 was the most frequent mutation site (44.7%) followed by exon 9 (21.1%) equally characterizing UV-induced common histotypes and ALM tumors. In mucosal melanoma exon 9 was the most frequently involved exon followed by exon 13 and 17. KIT mutation hotspots were identified in exon 9 (c482/491/492), in exon 11 (c559,c572, c570), in exon 13 (c642), in exon 17 (c822) and in exon 18 (c853). The relatively high KIT mutation rate in cutaneous melanoma in this central-European cohort justifies regular testing of this molecular target in this entity, not only in mucosal variants.

Indexed as

MutationEuropeExonsFemaleGene FrequencyHumansIncidenceMaleMelanomaMucous MembraneProto-Oncogene Proteins c-kitSkin NeoplasmsKIT protein, humanProto-Oncogene Proteins c-kitKIT mutation and sanger sequencingMucosal melanomaSkin melanoma

Identifiers

PMID31848942
PMCPMC7109162
OpenAlexW2996266550

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.